Updated:
ZyVersa Therapeutics
ZyVersa Therapeutics develops inflammasome-targeting drugs for renal and inflammatory diseases, led by IC 100.
ZyVersa Therapeutics
ZyVersa Therapeutics operates as a clinical-stage biopharmaceutical company headquartered in the United States. The firm is developing a pipeline of product candidates focused on renal and inflammatory diseases. Its foundational technology targets inflammasome inhibition, a pathway implicated in a range of serious conditions with limited treatment options. ZyVersa's lead candidate is IC 100, a monoclonal antibody designed to inhibit the ASC component of the inflammasome, which plays a role in driving damaging inflammation. The company is advancing IC 100 for indications including chronic kidney disease and other large-market inflammatory conditions. Its second pipeline asset, VAR 200, aims to regulate cholesterol efflux to address focal segmental glomerulosclerosis, a rare kidney disorder. The dual-asset strategy addresses both broad inflammatory pathways and specific renal pathologies. ZyVersa is listed on the Nasdaq Capital Market. Team size and specific principal executives are not confirmed from public record at this time. ZyVersa differentiates structurally from many peers by pursuing a dual-asset model that spans both rare and large-indication kidney diseases, with its inflammasome-targeting approach distinguishing its mechanism of action from more common cytokine-specific inhibitors.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
—
Corporate office
—
Sector focus
Frequently asked questions
What is ZyVersa's lead drug candidate and its mechanism of action?
ZyVersa's lead candidate is IC 100, a monoclonal antibody that inhibits the ASC component of the inflammasome. The inflammasome is a protein complex that triggers inflammatory responses; its dysregulation is linked to diseases like Alzheimer's, multiple sclerosis, and chronic kidney disease. By targeting ASC, IC 100 aims to reduce damaging inflammation across multiple tissues without completely suppressing the broader immune system.
What indications is ZyVersa targeting with its pipeline?
IC 100 is being developed for chronic kidney disease, with additional potential applications in other inflammatory conditions. ZyVersa's second asset, VAR 200, targets focal segmental glomerulosclerosis (FSGS), a rare kidney disorder that leads to scarring in the kidney's filtering units. This dual-asset pipeline gives ZyVersa exposure to both large-prevalence inflammation markets and a specific rare disease indication.
Is ZyVersa a family office or a life-sciences investment fund?
No. ZyVersa is a clinical-stage biopharmaceutical operating company, not a family office or investment fund. It conducts internal drug development, runs clinical trials, and raises capital through public equity markets as a Nasdaq-listed entity. It does not manage capital for external families or invest in third-party portfolio companies.
On which exchange is ZyVersa listed, and what is its corporate structure?
ZyVersa Therapeutics is a Delaware-registered corporation trading on the Nasdaq Capital Market. It develops therapies in-house and funds operations through equity offerings and licensing deals. It does not operate as a holding company for a family's diversified assets.
Who competes with ZyVersa in inflammasome-targeted therapies?
The inflammasome space includes competitors like Roche (through its acquisition of Inflazome) and Novartis, which have pursued NLRP3-specific inhibitors. ZyVersa's approach targets the shared ASC adaptor protein, which sits upstream of multiple inflammasome subtypes, potentially offering broader anti-inflammatory effects than inhibitors focused on a single inflammasome receptor.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: